Related Experiment Videos
Gout in the elderly. Clinical presentation and treatment
1Division of Rheumatology, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
Drugs & Aging
|October 28, 1998
Summary
Gout in the elderly presents uniquely, often affecting multiple joints and having a chronic course. Treatment requires careful drug selection due to increased risks in older patients.
Area of Science:
- Gerontology
- Rheumatology
- Clinical Pharmacology
Background:
- Gout in the elderly exhibits distinct characteristics compared to younger populations, including gender distribution, joint involvement, and clinical course.
- Risk factors for hyperuricemia and gout in seniors include diuretic use, renal insufficiency, aspirin, and alcohol abuse.
Purpose of the Study:
- To delineate the unique aspects of gout in the elderly.
- To review the challenges and recommendations for managing gout and hyperuricemia in aged individuals.
Main Methods:
- Literature review and clinical observation synthesis regarding geriatric gout.
- Analysis of pharmacological treatments and their safety profiles in elderly patients.
Main Results:
- Elderly gout often presents with polyarticular involvement, upper extremity joints, and a chronic indolent course with tophi.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) require extreme caution; short half-life options are preferred but contraindicated in certain conditions. Colchicine is poorly tolerated.
- Corticosteroids are an alternative for acute flares. Allopurinol is the preferred urate-lowering agent, but requires low-dose initiation (50-100mg alternate days, max 100-300mg daily) to mitigate hypersensitivity risks. Uricosurics are generally ineffective due to renal impairment.
Conclusions:
- Management of gout in the elderly necessitates careful consideration of comorbidities and drug toxicities.
- Low-dose allopurinol, guided by renal function, is recommended for chronic gout. Asymptomatic hyperuricemia does not warrant treatment due to toxicity risks.